Therefore, the CEA breast cancer screening tests miss a large number of patients with breast cancer depicted in Figure 5B. This wrong diagnosis becomes severer in the early-phased patients (grade I) with a sensitivity of 30.3% (Table 5). The gene discussed is CEACAM5; the disease is breast carcinoma.